SynthesisPediatric rheumatology online journal2021
Economic impact of Juvenile Idiopathic Arthritis: a systematic review.
Synthesis in Pediatric rheumatology online journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.Pediatric rheumatology online journal · 2024Trial
- Work Productivity Loss and Activity Impairment in Parents of Children With Juvenile Idiopathic Arthritis.ACR open rheumatology · 2026Article
- Digital home monitoring in patients with juvenile idiopathic arthritis to increase intervals of hospital visits.Rheumatology (Oxford, England) · 2026Article
- TAK1 inhibition restores p53 expression and suppresses inflammation and hyperplasia in JIA synovial fibroblasts.Rheumatology (Oxford, England) · 2026Article
- Work productivity and activity impairment in patients under 18 with juvenile idiopathic arthritis (JIA): the international UCAN CAN-DU prospective study.Arthritis research & therapy · 2026Article
- Association between asthma and juvenile idiopathic arthritis in children in the United States: a propensity score weighted cross-sectional study.Pediatric rheumatology online journal · 2026Article
- A Qualitative Exploration of Adherence to Methotrexate in Juvenile Idiopathic Arthritis.The Journal of pediatrics · 2026Article
- Carer quality of life in Switzerland: a cross-sectional study of parents of children affected by juvenile arthritis.Frontiers in public health · 2026Article
- Population Incidence and Burden of Juvenile Idiopathic Arthritis on Australian Health System: Data Linkage Study.Journal of paediatrics and child health · 2025Article
- A feasible treatment strategy for tapering subcutaneous tocilizumab in giant cell arteritis: a 24-month multi-center retrospective study.Rheumatology international · 2025Article
- Experiences among parents caring for children with juvenile idiopathic arthritis at a tertiary referral hospital in Kenya.Frontiers in pediatrics · 2025Article
- Development of a machine learning-based predictive nomogram for screening children with juvenile idiopathic arthritis: a pseudo-longitudinal study of 223,195 children in the United States.Frontiers in public health · 2025Article
- Modifications of the Effect of Juvenile Idiopathic Arthritis (JIA) on Anxiety and Depression in Children and Adolescents: A Pseudo-longitudinal Study of 192,019 Children in the United States.Clinical practice and epidemiology in mental health : CP & EMH · 2025Article
- Real-world psychosocial impact among patients with juvenile idiopathic arthritis and families in Spain.Pediatric rheumatology online journal · 2024Observational
- Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2024Article
- Uncovering the hidden socioeconomic impact of juvenile idiopathic arthritis and paving the way for other rare childhood diseases: an international, cross-disciplinary, patient-centered approach (PAVE Consortium).Pediatric rheumatology online journal · 2024Article
- Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain.Journal of health economics and outcomes research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile Idiopathic Arthritis (JIA) requires complex care that generate elevated costs, which results in a high economic impact for the family. The aim of this systematic review was to collect and cluster the information currently available on healthcare costs associated with JIA after the introduction of biological therapies.
methodsWe comprehensively searched in MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Databases for studies from January 2000 to March 2021. Reviewers working independently and in duplicate appraised the quality and included primary studies that report total, direct and/or indirect costs related to JIA for at least one year. The costs were converted to United States dollars and an inflationary adjustment was made.
resultsWe found 18 eligible studies including data from 6,540 patients. Total costs were reported in 10 articles, ranging from $310 USD to $44,832 USD annually. Direct costs were reported in 16 articles ($193 USD to $32,446 USD), showing a proportion of 55 to 98 % of total costs. Those costs were mostly related to medications and medical appointments. Six studies reported indirect costs ($117 USD to $12,385 USD). Four studies reported costs according to JIA category observing the highest in polyarticular JIA. Total and direct costs increased up to three times after biological therapy initiation. A high risk of reporting bias and inconsistency of the methodology used were found.
conclusionThe costs of JIA are substantial, and the highest are derived from medication and medical appointments. Indirect costs of JIA are underrepresented in costs analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.